<p>在 12 月 18 日，随着美国总统唐纳德·特朗普签署行政命令重新分类娱乐性药物并放宽相关限制，像 Canopy Growth (CGC)、Tilray Brands (TLRY) 和 Cronos Group (CRON) 这样的 cannabis 股票大幅上涨。</p>
<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>特朗普的命令将大麻重新分类为第三类药物，降低了其之前的第一类药物地位。其他第一类药物包括没有被接受的医疗用途的高度上瘾药物，如海洛因。较低级别的第三类药物被认为具有较低的滥用潜力，例如含有可待因的泰诺。</p>
<p>特朗普对大麻的重新分类被视为期待已久的里程碑。然而，行政命令并未允许合法的娱乐性销售。在白宫的一个仪式上，特朗普强调该行政命令并不合法化大麻，并且他 “绝不认可其作为娱乐性药物的使用”。</p>
<h2><strong>放宽大麻限制</strong></h2>
<p>在行政命令签署仪式上，特朗普和美国公共卫生官员表示，重新分类将使研究人员更容易研究大麻的影响及其潜在的医疗益处。</p>
<p>尽管如此，许多总部位于加拿大的美国上市大麻公司的股票在重新分类的消息传出后上涨了 3% 到 6%。该行业已经等待多年以便在美国重新分类大麻并放宽其使用限制。与此同时，交易员和投资者在很大程度上放弃了大麻股票。AdvisorShares 大麻 ETF 自 2021 年以来已下降超过 85%。</p>
<h2><strong>TLRY 股票值得购买吗？</strong></h2>
<p>Tilray 的股票在三位华尔街分析师中获得了一致的中等买入评级。该评级基于过去三个月内的两项买入和一项卖出建议。TLRY 的平均目标价为 7.00 美元，意味着从当前水平有 44.75% 的下行空间。</p>

CRON

TLRY

<p>大麻股票如 CGC、TLRY 和 CRON 在特朗普总统签署行政命令将大麻重新分类为第三类药物后大幅上涨，此举放宽了限制但并未合法化娱乐性使用。重新分类旨在促进对大麻医疗益处的研究。尽管股票上涨，AdvisorShares 大麻 ETF 自 2021 年以来已下跌超过 85%。Tilray 股票的评级为适度买入，价格目标暗示有 44.75% 的下行空间</p>

<p>Cannabis stocks such as Canopy Growth (CGC), Tilray Brands (TLRY), and Cronos Group (CRON) are up sharply on Dec. 18 after U.S. President Donald Trump signed an executive order to reschedule the recreational drug and ease restrictions around it.</p>
<div class="lb-trans"><p>在 12 月 18 日，随着美国总统唐纳德·特朗普签署行政命令重新分类娱乐性药物并放宽相关限制，像 Canopy Growth (CGC)、Tilray Brands (TLRY) 和 Cronos Group (CRON) 这样的 cannabis 股票大幅上涨。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Trump's order reclassifies cannabis as a Schedule III drug, lowering it from its previous Schedule I status. Other Schedule I substances include highly addictive drugs with no accepted medical use, such as heroin. Lower level Schedule III substances are considered to have reduced potential for abuse such as Tylenol with Codeine in it.</p>
<div class="lb-trans"><p>特朗普的命令将大麻重新分类为第三类药物，降低了其之前的第一类药物地位。其他第一类药物包括没有被接受的医疗用途的高度上瘾药物，如海洛因。较低级别的第三类药物被认为具有较低的滥用潜力，例如含有可待因的泰诺。</p>
</div><p>Trump's reclassification of cannabis is being applauded as a long-awaited milestone. However, the executive order stops short of permitting legalized recreational sales of the drug. In a White House ceremony, Trump stressed that the executive order doesn't legalize cannabis and that he &#34;in no way sanctions its use as a recreational drug.&#34;</p>
<div class="lb-trans"><p>特朗普对大麻的重新分类被视为期待已久的里程碑。然而，行政命令并未允许合法的娱乐性销售。在白宫的一个仪式上，特朗普强调该行政命令并不合法化大麻，并且他 “绝不认可其作为娱乐性药物的使用”。</p>
</div><h2><strong>Easing of Cannabis Restrictions</strong></h2>
<div class="lb-trans"><h2><strong>放宽大麻限制</strong></h2>
</div><p>In the executive order signing ceremony, Trump and U.S. public health officials said that the reclassification would enable researchers to more easily study the effects of cannabis and its potential medical benefits.</p>
<div class="lb-trans"><p>在行政命令签署仪式上，特朗普和美国公共卫生官员表示，重新分类将使研究人员更容易研究大麻的影响及其潜在的医疗益处。</p>
</div><p>Still, U.S.-listed shares of cannabis companies, many of which are based in Canada, rose between 3% and 6% on news of the reclassification. The industry has waited years for cannabis to be reclassified in the U.S. and restrictions around its use eased. In the meantime, traders and investors have largely abandoned cannabis stocks. The AdvisorShares cannabis ETF has declined more than 85% since 2021.</p>
<div class="lb-trans"><p>尽管如此，许多总部位于加拿大的美国上市大麻公司的股票在重新分类的消息传出后上涨了 3% 到 6%。该行业已经等待多年以便在美国重新分类大麻并放宽其使用限制。与此同时，交易员和投资者在很大程度上放弃了大麻股票。AdvisorShares 大麻 ETF 自 2021 年以来已下降超过 85%。</p>
</div><h2><strong>Is TLRY Stock a Buy?</strong></h2>
<div class="lb-trans"><h2><strong>TLRY 股票值得购买吗？</strong></h2>
</div><p>The stock of Tilray has a consensus Moderate Buy rating among three Wall Street analysts. That rating is based on two Buy and one Sell recommendations issued in the last three months. The average TLRY price target of $7.00 implies 44.75% downside from current levels.</p>
<div class="lb-trans"><p>Tilray 的股票在三位华尔街分析师中获得了一致的中等买入评级。该评级基于过去三个月内的两项买入和一项卖出建议。TLRY 的平均目标价为 7.00 美元，意味着从当前水平有 44.75% 的下行空间。</p>
</div>

CGC, TLRY, CRON: Cannabis Stocks Soar as Trump Reclassifies the Drug

Canopy Growth、Tilray Brands、Cronos：随着特朗普重新分类该药物，Cannabis 股票大涨